Therapure rolls-out commercial scale lyophilisation service

By Gareth Macdonald

- Last updated on GMT

Related tags: Manufacturing

Therapure Biopharma has added commercial-scale lyophilisation capacity at its facility Mississauga, Ontario in response to growing demand.

The Canadian contract development and manufacturing organisation (CDMO), which already provides clinical-scale lyophilisation and filling services, can now handle batch sized of up to 35,000 small vials or 3,000 200ml vials.

CEO Thomas Wellner told Outsourcing-pharma that the investment was motivated by an assessment of current and future drug industry lyophilisation capacity as customer requests for the service.

Wellner also suggested that further expansion is likely, explaining that: “We are expecting to fill our current lyophilisation by [capacity] 2012 and we have contracts which will require adding a 2nd and 3rd lyophilizer​.”

The move into commercial-scale lyophilisation fits with Therapure’s focus on the development and manufacture of therapeutic proteins and previously stated desire to set up a “one stop shop​”.

It is also in keeping with investments made by other CMOs in the last few months, most recently Swedish CDMO Recipharm which added large-scale lyophilisation capacity in January​.

Microbix deal

In other news, Therapure formed a manufacturing partnership with fellow Canadian virology and biological technologies firm Microbix Biosystems.

Under the deal, Therapure will take over the manufacture a range of “water-based” products for pharmaceutical and biotechnology manufacturing operations, which Micobix will market and sell.

Microbix CEO William Gastle explained that: "Therapure's capabilities will enable Microbix to expand our product line and market share of the growing water-based business in North America,”​ sales of which are growing 20 per cent a year.

Wellner was also positive about the deal, suggesting that: “This opportunity enables Therapure to leverage our large water and buffer manufacturing capacity and our Health Canada licensed aseptic filling capabilities​."

Related news

Related products

show more

Why Blister Packaging: Things to Consider

Why Blister Packaging: Things to Consider

Catalent Pharma Solutions | 03-Dec-2020 | Insight Guide

The decision to use blister packaging for either clinical trials or commercial drug manufacturing comes with a host of factors to consider. Pharmaceutical...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Related suppliers

Follow us


View more